ZA914491B - Inhibition of 5-lipoxygenase and cyclooxygenase products - Google Patents

Inhibition of 5-lipoxygenase and cyclooxygenase products

Info

Publication number
ZA914491B
ZA914491B ZA914491A ZA914491A ZA914491B ZA 914491 B ZA914491 B ZA 914491B ZA 914491 A ZA914491 A ZA 914491A ZA 914491 A ZA914491 A ZA 914491A ZA 914491 B ZA914491 B ZA 914491B
Authority
ZA
South Africa
Prior art keywords
lipoxygenase
inhibition
cyclooxygenase products
cyclooxygenase
products
Prior art date
Application number
ZA914491A
Other languages
English (en)
Inventor
Jerry Leroy Adams
Leroy Adams Jerry
Timothy Francis Gallagher
Francis Gallagher Timothy
Carl Perchonock
Perchonock Carl
Paul Elliot Bender
Elliot Bender Paul
John Richard Heys
Richard Heys John
Anthony John Villani
John Villani Anthony
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ZA914491B publication Critical patent/ZA914491B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA914491A 1990-06-12 1991-06-10 Inhibition of 5-lipoxygenase and cyclooxygenase products ZA914491B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53719590A 1990-06-12 1990-06-12

Publications (1)

Publication Number Publication Date
ZA914491B true ZA914491B (en) 1992-12-30

Family

ID=24141624

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA914491A ZA914491B (en) 1990-06-12 1991-06-10 Inhibition of 5-lipoxygenase and cyclooxygenase products

Country Status (10)

Country Link
EP (1) EP0533837A4 (xx)
JP (1) JPH05508153A (xx)
KR (1) KR930700104A (xx)
AU (1) AU8205991A (xx)
CA (1) CA2084290A1 (xx)
IE (1) IE911977A1 (xx)
NZ (1) NZ238485A (xx)
PT (1) PT97960A (xx)
WO (1) WO1991019497A1 (xx)
ZA (1) ZA914491B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679396A1 (en) * 1994-03-02 1995-11-02 Pfizer Inc. Use of 3-substituted-2-oxidole-1-carboxamides for the manufacture of a medicament in the treatment and prevention of ischemia induced myocardial injury and cytokine mediated myocardial injury
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
EP0833622B8 (en) * 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
AU744997B2 (en) 1997-09-05 2002-03-07 Glaxo Group Limited 2,3-diaryl-pyrazolo(1,5-B)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
AR017219A1 (es) 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1112070B1 (en) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
DE69919887T2 (de) 1998-11-03 2005-09-15 Glaxo Group Ltd., Greenford Pyrazolopyridin derivative als selektive cox-2 inhibitoren
DE69914357T2 (de) 1998-11-04 2004-11-11 Smithkline Beecham Corp. Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
ATE261444T1 (de) 1999-02-27 2004-03-15 Glaxo Group Ltd Pyrazolopyridine
PT1140939E (pt) 1999-11-10 2005-05-31 Ortho Mcneil Pharm Inc 2-aril-3-(heteroaril)- imidazo [1,2-alfa] pirimidinas substituidas, e formulacoes farmaceuticas e metodos relacionados
WO2001038312A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS
ES2241675T3 (es) 1999-11-23 2005-11-01 Smithkline Beecham Corporation Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de cspb/p38 quinasa.
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
DE60112330T2 (de) 2000-12-15 2006-04-13 Glaxo Group Ltd., Greenford Pyrazolopyridinderivate
US6919352B2 (en) 2000-12-15 2005-07-19 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
DE60201074T2 (de) 2001-03-08 2005-09-15 Smithkline Beecham Corp. Pyrazolopyridinderivate
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
WO2002078700A1 (en) 2001-03-30 2002-10-10 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapteutic compounds
WO2002083672A1 (en) 2001-04-10 2002-10-24 Smithkline Beecham Corporation Antiviral pyrazolopyridine compounds
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
WO2002088124A2 (en) 2001-04-27 2002-11-07 Smithkline Beecham Corporation Pyrazolo'1,5-a!pyridine derivatives
CN1518550A (zh) * 2001-06-21 2004-08-04 ʷ��˿�������ȳ�ķ���޹�˾ 用于预防和治疗疱疹病毒感染的咪唑并[1,2-a]吡啶衍生物
US7244740B2 (en) 2001-10-05 2007-07-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
JP2005516916A (ja) 2001-12-11 2005-06-09 スミスクライン ビーチャム コーポレーション 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体
AU2003275266A1 (en) 2002-10-03 2004-05-04 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
WO2007028051A2 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
EP2493889B1 (en) 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
EP2518066B1 (en) 2009-12-18 2016-05-18 Mitsubishi Tanabe Pharma Corporation Novel anti-platelet agent
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
EP2863909B1 (en) 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
MX362197B (es) 2012-07-09 2019-01-08 Janssen Pharmaceutica Nv Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW24186A1 (en) * 1985-12-12 1987-07-08 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US5002941A (en) * 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
AU6355190A (en) * 1989-06-13 1991-01-17 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages

Also Published As

Publication number Publication date
IE911977A1 (en) 1991-12-18
EP0533837A4 (en) 1994-11-17
WO1991019497A1 (en) 1991-12-26
EP0533837A1 (en) 1993-03-31
CA2084290A1 (en) 1991-12-13
NZ238485A (en) 1994-03-25
PT97960A (pt) 1992-03-31
JPH05508153A (ja) 1993-11-18
KR930700104A (ko) 1993-03-13
AU8205991A (en) 1992-01-07

Similar Documents

Publication Publication Date Title
ZA914491B (en) Inhibition of 5-lipoxygenase and cyclooxygenase products
ZA912432B (en) Elastomers and products having reduced hysteresis
ZA893578B (en) Novel hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
ZA911101B (en) Inhibition of modified ldl products
KR100321237B1 (ko) 적층구조물
EP0471508A3 (en) Power capacitor and method of making the same
PL311300A1 (en) 4-arylo-4-hydroxy-tetrahydropyranes and 3-arylo-3-hydroxy-tetrahydrofuranes as inhibitors of 5-lipoxygenase
PL294074A1 (en) Gelly preparations of harmful products
GB9021234D0 (en) Treatment of food and other products
HU9501810D0 (en) Cyclooxygenase and 5-lipoxygenase inhibiting n(3-biphenylyl-1(s)-methyl-2-propenyl) acetohydroxamic acid derivatives
GB9202653D0 (en) Improvements relating to the microwave processing of materials
EP0456138A3 (en) Peptide-amidase and its application
EP0488942A3 (en) Method and device to control the temperature of objects especially column-analyzers and their use
ZA916619B (en) Articles of bedding and the like
HU9302018D0 (en) Pre-compounds of quinoline and naphthydryl
GB9114896D0 (en) Identification of materials and products
AU6574994A (en) Cyclooxygenase and 5-lipoxygenase inhibiting hydroxamic acid derivatives
GB9100915D0 (en) Products and process
GB9026257D0 (en) Thiazole derivatives and their preparation
GB9119672D0 (en) Handling of slabs and the like
GB9021446D0 (en) Documents and processing of documents
GB9218828D0 (en) Documents and processing of documents
ZA939510B (en) Subsituted 4-phenyl-pyridones and 4-phenyl2-2alkoxypyridines
IL98982A0 (en) Inhibitors of fucosyltransferase and their uses
GB9212254D0 (en) Sheet materials and methods of making sheet materials